The discovery of novel auristatin derived antibody drug conjugates (ADCs) with attenuated bystander activity is an area of intense research. Recently, the drug-linker SGD-9501 emerged as a promising clinical candidate possessing favorable off-target toxicity. To support clinical supply of ADCs based on this drug-linker, we set out to develop a synthesis to enable a first-in-human (FIH) amenable Good Manufacturing Practice (GMP) delivery. This presentation will describe the process development activities that enabled kilogram-scale supply. Highlights of the fragment synthesis include the development and implementation of a crystallization platform, the use of process analytical technology (PAT) to control impurities formed in a direct coupling of N,N-dimethyl-O-unprotected serine, and the discovery of mild and selective deprotection conditions. The late stages of the synthesis will be presented with a focus on how we address certain problems that are unique to large molecules such as gelation risks caused by eutectic effects, and trifluoroacetate ester impurities formed during lyophilization.
College of Science and Technology
OPEN TO: Undergraduate Students, Graduate Students, Faculty and Staff